NCT06609343View on ClinicalTrials.gov

Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 18, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

November 30, 2026

Conditions
End Stage Renal DiseaseFatigue
Interventions
DRUG

Bupropion Hydrochloride 150 MG

Bupropion Hydrochloride Extended Release is administered orally three times a week during routine dialysis sessions for 8 consecutive weeks

Trial Locations (1)

78229

RECRUITING

University Hospital Dialysis Medical Center (DMC), San Antonio

All Listed Sponsors
lead

The University of Texas Health Science Center at San Antonio

OTHER